ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulin G

Also written as “HYQVIA”, “HyQvia” and “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”.

Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Prostatic Neoplasms · Autoimmune Diseases of the Nervous System · Alzheimer Disease, led by 6 companies.

Drug pageImmunoglobulin G: every studyMany companies study it; this page follows only the 13 they lead. All 241 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201713 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only60 open or runningphase 4since Apr 12, 2017Sep 11, 2015none ahead
GC Biopharma30 open or runningphase 4since Jan 25, 2012Mar 14, 2011none ahead
CSLits history only10 open or runningphase 3since May 16, 2008May 16, 2008none ahead
Genmabits history only10 open or runningphase 2since May 14, 2020May 14, 2020none ahead
Hoffmann-La Rocheits history only10 open or runningphase 1since May 30, 2025May 30, 2025none ahead
Proclara Biosciencesits history only10 open or runningphase 1since Dec 23, 2016Dec 23, 2016none ahead

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, AbbVie and Symyoo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GC Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2011First study: phase 3 study in SepsisFirst studyNCT01315496 · 214 enrolled · Korea, Republic of
  2. Jan 25, 2012Phase 4 study in Mucocutaneous Lymph Node SyndromeNCT01524939 · 45 enrolled · Korea, Republic of
  3. Nov 21, 2019Phase 2 study in Autoimmune Diseases of the Nervous SystemNCT04175522 · 23 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 GC Biopharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04175522Autoimmune Diseases of the Nervous System · Korea, Republic of2CompletedJun 11, 202023
NCT01524939Mucocutaneous Lymph Node Syndrome · Korea, Republic of4CompletedSep 201245
NCT01315496Sepsis · Korea, Republic of3TerminatedDec 2013214

How it is read

Names in the registry

  • “HYQVIA”, 10 entries
  • “Immunoglobulin G”, 3 entries
  • “HyQvia”, 1 entry
  • “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”, 1 entry
  • “NPT088”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.